Major response to cyclophosphamide and prednisone in recurrent castration-resistant prostate cancer

Nicolas Batty, Naveen Yarlagadda, Roberto Pili

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

Prostate cancer is the most common noncutaneous cancer among men. This case report describes a 43-year-old man with rapidly progressing castration-resistant prostate cancer (CRPC) that responded initially to docetaxel and did not tolerate cabazitaxel. He subsequently received a third line of chemotherapy with cyclo-phosphamide and prednisone, and experienced a dramatic clinical and radiographic response in his liver metastases. This therapeutic intervention led to a significant clinical benefit and confirms the potential use of cyclophosphamide in patients with CRPC, particularly those with liver metastases.

Original languageEnglish (US)
Pages (from-to)911-915
Number of pages5
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume11
Issue number8
DOIs
StatePublished - Aug 1 2013
Externally publishedYes

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Major response to cyclophosphamide and prednisone in recurrent castration-resistant prostate cancer'. Together they form a unique fingerprint.

  • Cite this